Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Deffered Revenue (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $3.5 million as the latest value for Q2 2019.

  • On a quarterly basis, Non-Current Deffered Revenue rose 15.41% to $3.5 million in Q2 2019 year-over-year; TTM through Jun 2019 was $3.5 million, a 15.41% increase, with the full-year FY2018 number at $2.8 million, down 38.25% from a year prior.
  • Non-Current Deffered Revenue was $3.5 million for Q2 2019 at Outlook Therapeutics, down from $4.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $12.7 million in Q3 2015 to a low of $2.8 million in Q3 2018.
  • A 5-year average of $4.8 million and a median of $4.5 million in 2017 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 59.51% in 2016, then rose 23.46% in 2019.
  • Outlook Therapeutics' Non-Current Deffered Revenue stood at $12.7 million in 2015, then tumbled by 61.89% to $4.9 million in 2016, then fell by 16.87% to $4.0 million in 2017, then rose by 16.58% to $4.7 million in 2018, then fell by 24.84% to $3.5 million in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Non-Current Deffered Revenue are $3.5 million (Q2 2019), $4.1 million (Q1 2019), and $4.7 million (Q4 2018).